Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Six of Oxford University's distinguished scientists, and four from the Medical Sciences Division, have been elected as Fellows of the Royal Society for their outstanding contributions to science.

© OUI/Greg Smolonski

Image credit: OUI/Greg Smolonski

This year’s Fellows are:

Professor Neil Brockdorff FRS, Wellcome Trust Principal Research Fellow, Department of Biochemistry, University of Oxford.

Professor Vincenzo Cerundolo FMedSci FRS, Director, MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford. The award recognises Professor Cerundolo’s world leading research on T cell immunology, particularly his discoveries on how peptides and lipids are processed and presented to T cells. This research has opened new therapeutic avenues. ‘I am extremely honoured and humbled to be receiving such an important recognition,’ said Professor Cerundolo, ‘I am certain that working in the exciting and vibrant environment of the MRC WIMM and being able to collaborate with so many outstanding colleagues has contributed enormously to this achievement.’ Find out more.

Professor Andrew King FMedSci FRS, Wellcome Trust Principal Research Fellow and Professor of Neurophysiology, Department of Physiology, Anatomy and Genetics, University of Oxford. Find out more.

Professor Dominic Kwiatkowski FMedSci FRS, Head of Parasites and Microbes Programme, Wellcome Sanger Institute and Professor of Genomics and Global Health, University of Oxford. Professor Kwiatkowski said: ‘I am honoured to be elected to the Fellowship of the Royal Society. It is a testimony to the amazing creativity and teamwork that is going on at Sanger and Oxford, and among all our partners in the MalariaGEN network. It is a great privilege to work with colleagues who are so committed to gaining a deep scientific understanding of malaria, not only as a fascinating biological problem, but also as a critical step in reducing the burden of disease in the poorest parts of the world.’

Professor Graham Richards CBE FRS, Chairman and Founder, Oxford Drug Design Ltd and Professor, Department of Chemistry, University of Oxford.

Professor Guy Wilkinson FRS, Professor of Physics, Department of Physics, University of Oxford.

Find out more (University of Oxford)

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.